menu
    • menu
    [{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Mesalazine","moa":"PPAR-gamma","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zeria Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Zeria Pharmaceutical \/ Kyowa Kirin"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mesalazine","moa":"COX","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Extended-release Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mesalazine","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Anbison","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Mesalazine","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Anbison","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Anbison \/ Ethypharm","highestDevelopmentStatusID":"12","companyTruncated":"Anbison \/ Ethypharm"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mesalazine","moa":"COX\/Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Mesalazine

    Menu

    Mesalazine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Amneal Pharmaceuticals

    U.S.A arrow
    ELCC
    Not Confirmed

    Amneal Pharmaceuticals

    U.S.A arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mesalazine

    Therapeutic Area : Gastroenterology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

    Details : Asacol HD-Generic (mesalamine) is an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults.

    Product Name : Asacol HD-Generic

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 19, 2025

    Lead Product(s) : Mesalazine

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Anbison

    China arrow
    ELCC
    Not Confirmed

    Anbison

    China arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mesalazine

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : Ethypharm

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

    Details : The acquisition will enable Ethypharm a full portfolio of Mesalazine forms, including a suppository form of Etiasa (mesalazine), used to treat IBD such as ulcerative colitis and Crohn's disease.

    Product Name : Etiasa

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    June 13, 2024

    Lead Product(s) : Mesalazine

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : Ethypharm

    Deal Size : Undisclosed

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Upsher-Smith Laboratories

    U.S.A arrow
    ELCC
    Not Confirmed

    Upsher-Smith Laboratories

    U.S.A arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mesalazine

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Upsher-Smith Expands Generics Portfolio with Launch of Mesalamine Extended-Release Capsules, USP

    Details : Mesalamine, also known as 5-aminosalicylic acid extended-release capsule is a small molecule, which is indicated for the maintenance of remission of ulcerative colitis in adults.

    Product Name : Apriso-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    August 21, 2023

    Lead Product(s) : Mesalazine

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Zydus Lifesciences

    India arrow
    ELCC
    Not Confirmed

    Zydus Lifesciences

    India arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mesalazine

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Zydus Cadila Receives US FDA Approval for Mesalamine ER Capsules

    Details : Mesalamine Extended-Release capsules are indicated for the maintenance of remission of ulcerative colitis in adults. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    August 13, 2021

    Lead Product(s) : Mesalazine

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Zeria Pharmaceutical

    Japan arrow
    ELCC
    Not Confirmed

    Zeria Pharmaceutical

    Japan arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mesalazine

    Therapeutic Area : Gastroenterology

    Study Phase : Approved

    Sponsor : Kyowa Kirin

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Kyowa Kirin Terminates ASACOL® deal with Zeria Pharmaceutical

    Details : Kyowa Kirin will finish its commercialization activity for ASACOL on March 31, 2020, and Zeria will obtain the full rights of the commercialization activities for ASACOL from April 1, 2020.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    February 03, 2020

    Lead Product(s) : Mesalazine

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved

    Sponsor : Kyowa Kirin

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth